Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 10/20 | 0.62 |
| ▸ | BCR | P11274 | 7/20 | 0.62 |
| ▸ | BRAF | P15056 | 5/20 | 0.62 |
| ▸ | LYN | P07948 | 4/20 | 0.62 |
| ▸ | CSK | P41240 | 2/20 | 0.62 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.62 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.62 |
| ▸ | LCK | P06239 | 1/20 | 0.62 |
| ▸ | FYN | P06241 | 1/20 | 0.62 |
| ▸ | RET | P07949 | 1/20 | 0.62 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.62 |
| ▸ | ARAF | P10398 | 1/20 | 0.62 |
| ▸ | NQO2 | P16083 | 1/20 | 0.62 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.62 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.62 |
| ▸ | ABL2 | P42684 | 1/20 | 0.62 |
| ▸ | FRK | P42685 | 1/20 | 0.62 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.62 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.62 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10054813 | 1.00 | ABL1 (0.62) | ABL1BCRBRAFLYNCSK | |
| SCHEMBL2679169 | 1.00 | ABL1 (0.62) | ABL1BCRBRAFLYNCSK | |
| SCHEMBL10054814 | 1.00 | ABL1 (0.62) | ABL1BCRBRAFLYNCSK | |
| SCHEMBL2679171 | 1.00 | ABL1 (0.62) | ABL1BCRBRAFLYNCSK | |
| SCHEMBL2679318 | 0.93 | ABL1 (0.68) | ABL1BCRBRAFLYNCSK | |
| SCHEMBL2679315 | 0.93 | ABL1 (0.68) | ABL1BCRBRAFLYNCSK | |
| SCHEMBL10054837 | 0.93 | ABL1 (0.68) | ABL1BCRBRAFLYNCSK | |
| SCHEMBL2679484 | 0.93 | ABL1 (0.68) | ABL1BCRBRAFLYNCSK | |
| SCHEMBL10054838 | 0.93 | ABL1 (0.68) | ABL1BCRBRAFLYNCSK | |
| SCHEMBL10078204 | 0.91 | ABL1 (0.52) | ABL1BCRBRAFLYNCSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102421754-B | Acrylamide derivative and use thereof in manufacture of medicament | BEIJING SHIQIAO BIOPHAM CO LTD | 2013-11-27 | — | — | CN | claimed |
| US-8426446-B2 | Acrylamide derivative and use thereof in manufacture of medicament | BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) | 2013-04-23 | — | — | US | claimed |
| US-20120116075-A1 | Acrylamide Derivative And Use Thereof In Manufacture Of Medicament | BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD | 2012-05-10 | — | — | US | claimed |
| CN-102421754-B | Acrylamide derivative and use thereof in manufacture of medicament | BEIJING SHIQIAO BIOPHAM CO LTD | 2013-11-27 | — | — | CN | disclosed |
| US-8426446-B2 | Acrylamide derivative and use thereof in manufacture of medicament | BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) | 2013-04-23 | — | — | US | disclosed |
| US-20120116075-A1 | Acrylamide Derivative And Use Thereof In Manufacture Of Medicament | BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116075-A1 | Acrylamide Derivative And Use Thereof In Manufacture Of Medicament | ABL1, ABL2, BCR | ABL1 1/4885BCR 3/4885BRAF 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.